Home

Articles from Heartflow Holding, Inc.

Heartflow Plaque Analysis to be Covered by UnitedHealthcare Plans Nationwide
Largest commercial insurer in the United States releases positive comprehensive coverage for AI-enabled Heartflow Plaque Analysis to support precise diagnosis and management of patients
By Heartflow Holding, Inc. · Via GlobeNewswire · July 22, 2025
Heartflow Unveils Landmark DECIDE Registry Data Demonstrating Impact of Heartflow Plaque Analysis on Coronary Artery Disease Medical Management
More than 50% of patients saw treatment changes following Heartflow Plaque Analysis – driving promising LDL cholesterol improvements and individualized care
By HeartFlow Holding, Inc. · Via GlobeNewswire · July 17, 2025
Heartflow Plaque Analysis Awarded First Coverage Recommendation by Radiology Benefits Manager
EviCore’s updated coverage guidelines support access to AI-enabled Plaque Analysis to help physicians precisely diagnose and manage patients with coronary artery disease
By HeartFlow Holding, Inc. · Via GlobeNewswire · July 11, 2025
Heartflow to Showcase Landmark DECIDE Data at SCCT 2025, Advancing AI-Driven Care for Coronary Artery Disease
DECIDE Registry receives top award as company plans to unveil the next generation plaque technology at SCCT Annual Scientific Meeting
By HeartFlow Holding, Inc. · Via GlobeNewswire · June 30, 2025
Heartflow Closes $98 Million Convertible Notes Financing
Additional Capital to Support Broadening Adoption of a Leading Platform That Transforms Diagnosis and Management of Coronary Artery Disease
By HeartFlow Holding, Inc. · Via GlobeNewswire · March 26, 2025
Heartflow Unveils Bold New Vision for Management of Coronary Artery Disease
New Brand Identity Reaffirms Commitment to Transforming the World’s Leading Cause of Death Into a Manageable Condition
By HeartFlow Holding, Inc. · Via GlobeNewswire · February 25, 2025
NFL Alumni Joel Dreessen and Le-Lo Lang Team Up With HeartFlow and Boone Heart Institute to Launch GAMEFILM Registry to Assess Heart Disease Risks in Retired Football Players
Registry will use HeartFlow FFRCT and Plaque Analysis to help inform strategies for prevention, earlier detection and improved care for former NFL athletes at high risk for coronary artery disease
By HeartFlow Holding, Inc. · Via GlobeNewswire · January 22, 2025
HeartFlow Announces New Decision from Centers for Medicare & Medicaid Services Boosting CCTA Reimbursement and Access
— Hospital Outpatient Prospective Payment System reimbursement rate doubled, expanding access to CCTA and supporting the technology’s superior accuracy and efficiency in cardiac care
By HeartFlow Holding, Inc. · Via GlobeNewswire · November 1, 2024
Positive Long-term Outcomes with HeartFlow FFRCT and Plaque Analysis Demonstrated in ADVANCE-DK Registry at TCT 2024
— Data confirm the use of FFRCT and Plaque Analysis helps assess long-term risks, informing more personalized and effective treatment plans for patients with coronary artery disease
By HeartFlow Holding, Inc. · Via GlobeNewswire · October 27, 2024
HeartFlow Announces New Category I CPT Code from the American Medical Association for AI-Enabled Plaque Analysis to Assess Risk for Coronary Artery Disease
New reimbursement code follows recent favorable Medicare coverage decision, expanding access to HeartFlow’s Plaque Analysis to help physicians provide personalized treatment plans
By HeartFlow Holding, Inc. · Via GlobeNewswire · October 18, 2024
HeartFlow to Present Latest Data on AI-Enabled Coronary Artery Disease Management at TCT 2024
Long-term outcomes data from ADVANCE-DK Registry with HeartFlow FFRCT and Plaque Analysis and ongoing clinical studies highlighting CCTA and FFRCT diagnostic pathway to be discussed in six presentations
By HeartFlow Holding, Inc. · Via GlobeNewswire · October 14, 2024
HeartFlow Announces Favorable Coverage Determination for Plaque Analysis by Four Medicare Administrative Contractors
Coverage policy improves access to artificial intelligence-enabled plaque analysis providing insights to help physicians guide treatment decisions for patients with coronary artery disease
By HeartFlow Holding, Inc. · Via GlobeNewswire · October 11, 2024
HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease
Technology offers benefits of HeartFlow Plaque Analysis with the new addition of 3D interactive capabilities, integrated with lesion specific FFRCT values
By HeartFlow Holding, Inc. · Via GlobeNewswire · July 18, 2024
SCCT 2024: HeartFlow to Present New Data on Coronary Artery Disease Management with Coronary Computed Tomography Angiography
MOUNTAIN VIEW, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- HeartFlow, a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced it will be presenting new findings on the use of coronary computed tomography angiography (coronary CTA) in coronary artery disease (CAD) management and insights on CTA reimbursement at the upcoming 19th Annual Scientific Meeting of SCCT. The annual meeting will take place on July 18-21, 2024 in Washington, D.C.
By HeartFlow Holding, Inc. · Via GlobeNewswire · July 16, 2024
HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage
Coverage policy determination initiated with 5 Medicare MACs for HeartFlow's AI-QCT revolutionizing cardiovascular care for patients
By HeartFlow Holding, Inc. · Via GlobeNewswire · June 3, 2024
HeartFlow's Plaque Analysis Leading The Way: 95% Accuracy vs Invasive Imaging In Newly Published REVEALPLAQUE Study
MOUNTAIN VIEW, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that the data from its REVEALPLAQUE study, highlighting the accuracy of its Plaque Analysis, was published in the European Heart Journal Cardiovascular Imaging.
By HeartFlow Holding, Inc. · Via GlobeNewswire · May 15, 2024
HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients
First published evidence: FFRCT-guided diagnosis and treatment drastically reduces mortality in peripheral artery disease (PAD) patients
By HeartFlow Holding, Inc. · Via GlobeNewswire · May 8, 2024
HeartFlow Initiates DECIDE Registry to Evaluate Utility of HeartFlow AI-Enabled Plaque Analysis for Patients with Suspected Coronary Artery Disease
The largest prospective registry of its kind will build upon clinical data supporting the use of plaque insights to empower clinical decision making for patients with suspected coronary artery disease
By HeartFlow Holding, Inc. · Via GlobeNewswire · March 26, 2024
HeartFlow Announces Publication of 10-year Follow-Up Data from the DISCOVER-FLOW Study in the Journal of Cardiovascular Computed Tomography
HeartFlow's non-invasive AI driven FFRCT predicts patient outcomes as effectively as the gold-standard invasive FFR out to 10 years
By HeartFlow Holding, Inc. · Via GlobeNewswire · March 12, 2024
HeartFlow Announces New Reimbursement Code and Increased Payment for FFRCT
Category I CPT code for Fractional Flow Reserve derived from Computed Tomography will provide broader access to HeartFlow’s AI-powered technology, a standard of care for evaluating and treating coronary artery disease
By HeartFlow Holding, Inc. · Via GlobeNewswire · January 23, 2024
HeartFlow Achieves Landmark Milestone of 250,000 Patients Assessed for Coronary Artery Disease (CAD) with FFRCT Analysis
This patient milestone and the recent launch of Plaque Analysis and RoadMap™ Analysis further solidify HeartFlow as a pioneer in AI-enabled CAD diagnostics
By HeartFlow Holding, Inc. · Via GlobeNewswire · January 3, 2024
TCT 2023: HeartFlow Presents Clinical Data Featuring First Solution Offering Lesion-Specific Insights
New Clinical Data Support Use of Lesion-Specific FFRCT for Diagnosis and Treatment of Patients With Coronary Artery Disease
By HeartFlow Holding, Inc. · Via GlobeNewswire · October 25, 2023
New Data from Clinical Studies Further Validate HeartFlow’s All-in-One Portfolio of Precision Coronary Care Solutions
Primary endpoints across three studies underscore the importance of accuracy, utility, and efficiency in coronary artery disease diagnostics and clinical decision making
By HeartFlow Holding, Inc. · Via GlobeNewswire · July 28, 2023
HeartFlow, Inc. to Announce New Data on Diagnosing and Managing Coronary Artery Disease at the 2023 Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting
MOUNTAIN VIEW, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the only non-invasive precision coronary care solution to provide both anatomic and physiologic insights, today announced that new data on HeartFlow Plaque Analysis and its RoadMapTM Analysis will be presented at the 2023 Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Boston, MA.
By HeartFlow Holding, Inc. · Via GlobeNewswire · July 24, 2023
New HeartFlow RoadMap™ Analysis Now Available in U.S. to Assist CT Readers in Identifying Coronary Artery Narrowings
Non-invasive, AI-enabled product helps CT readers to accurately*, efficiently, and consistently identify narrowings in the coronary arteries, advancing the HeartFlow portfolio
By HeartFlow Holding, Inc. · Via GlobeNewswire · April 17, 2023
HeartFlow, Leader in Revolutionizing Precision Heart Care, Closes $215 Million in Series F Funding Led by Bain Capital Life Sciences
Financing will further drive commercial scale for HeartFlow’s AI-enabled portfolio of precision heart care products
By HeartFlow Holding, Inc. · Via GlobeNewswire · April 6, 2023
CORRECTION -- Late-breaking Data Demonstrate AHA/ACC Guideline-directed CCTA ± FFRCT Precision Pathway is Superior to Traditional Testing
Using coronary computed tomography angiography (CCTA) with HeartFlow’s FFRCT Analysis to evaluate suspected coronary artery disease (CAD) offers more accurate non-invasive diagnosis, fewer unnecessary tests, and higher confidence in identifying patients needing treatment
By HeartFlow Holding, Inc. · Via GlobeNewswire · November 6, 2022
Late-breaking Data Demonstrate AHA/ACC Guideline-directed CCTA ± FFRCT Precision Pathway is Superior to Traditional Testing
Using coronary computed tomography angiography (CCTA) with HeartFlow’s FFRCT Analysis to evaluate suspected coronary artery disease (CAD) offers more accurate non-invasive diagnosis, fewer unnecessary tests, and higher confidence in identifying patients needing treatment
By HeartFlow Holding, Inc. · Via GlobeNewswire · November 6, 2022
HeartFlow Receives FDA 510(k) Clearance for its Plaque Analysis and RoadMap™ Analysis
HeartFlow is the first and only company to provide non-invasive anatomy, physiology, and plaque information based on coronary computed tomography angiography (CCTA)
By HeartFlow Holding, Inc. · Via GlobeNewswire · October 18, 2022
HeartFlow Announces Late Breakers Presentation at the 2022 American Heart Association (AHA) Scientific Sessions
12 month data from The PRECISE Trial, the first global, prospective, randomized trial comparing diagnosis and evaluation pathways for stable chest pain, will be presented at the AHA 2022 Scientific Sessions.
By HeartFlow Holding, Inc. · Via GlobeNewswire · October 3, 2022
HeartFlow Holding, Inc. Provides Selected Preliminary Second Quarter 2021 Financial Results and Updated Guidance for Full Year 2021
HeartFlow Holding, Inc. (“HeartFlow” or the “Company”), the leader in revolutionizing precision heart care, today announced selected preliminary financial results for the period ended June 30, 2021 and provided updated guidance for the year ending December 31, 2021.
By HeartFlow Holding, Inc. · Via Business Wire · September 14, 2021
HeartFlow, the Leader in Precision Heart Care, Announces Merger with Longview Acquisition Corp. II to Become a Publicly Traded Company
HeartFlow Holding, Inc. (“HeartFlow”, or the “Company”), the leader in revolutionizing precision heart care, and Longview Acquisition Corp. II (NYSE: LGV) (“Longview”), a special purpose acquisition company sponsored by affiliates of Glenview Capital Management, LLC (“Glenview”), announced today that they have entered into a definitive business combination agreement that will support HeartFlow’s vision of revolutionizing precision heart care. Upon completion of the proposed transaction, the combined company will operate as HeartFlow Group, Inc. and is expected to be listed on the New York Stock Exchange (“NYSE”) under the symbol “HFLO.” The transaction will also provide the combined company with an estimated $400 million in cash for growth capital, product development and general corporate purposes.
By HeartFlow Holding, Inc. · Via Business Wire · July 15, 2021